Hamburg - Delayed Quote EUR

Viromed Medical AG (VMED.HM)

4.8200

+0.2400

+(5.24%)

At close: 10:35:21 AM GMT+2

Viromed Medical AG: UMECO Group Acquires Exclusive Marketing Rights in Asia for Cold Plasma Medical Devices ViroCAP(R) and PulmoPlas(R)

PINNEBERG, DE / ACCESS Newswire / April 1, 2025 / Viromed Medical AG ("Viromed", ticker:VMED; ISIN:DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in air disinfection, wound healing and intensive ...

ACCESS Newswire 27 days ago

VMED.F
Viromed Medical AG Reports Promising Study Results for PulmoPlas(R) in Intensive Care Unit Ventilator-Associated Pneumonia Patients

PINNEBERG, GERMANY / ACCESS Newswire / March 14, 2025 / Viromed Medical AG ("Viromed", Ticker:VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in room air sterilization, wound healing, ...

ACCESS Newswire last month

VMED.F
Viromed Medical AG reaches milestone for cooperation with multinational corporation

PINNEBERG, Germany, February 28, 2025--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a man

Business Wire last month

VMED.F
Viromed Medical AG: Cold Plasma as a Digital Antibiotic for the Lungs

PINNEBERG, Germany, November 26, 2024--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; "Viromed") is pushing forward research into cold plasma for the prevention of ventilator-associated pneumonia (VAP). Under the scientific direction of the outstanding expert Prof. Dr. Hortense Slevogt, BREATH scientist at the Hannover Medical School, the innovative project is investigating the safety and efficacy of cold plasma to kill bacteria in the respiratory tract for approval as a therapy.

Business Wire 4 months ago

VMED.F
Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights

PINNEBERG, Germany, September 17, 2024--Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; "Viromed"; the "Company") plans to acquire all shares in ActivCell Group AG, Switzerland, and thus strategically expand its product portfolio. To this end, the Company has today signed a term sheet with the owners of ActivCell Group AG and will immediately enter into further negotiations with the objective of concluding an agreement. With the acquisition of ActivCell Group AG, Viromed expands the treatm

Business Wire 7 months ago

VMED.F

Performance Overview

Return	VMED.HM	DAX P (^GDAXI)
YTD	+104.24%	+11.87%
1-Year	+100.83%	+22.63%
3-Year	+192.12%	+59.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viromed Medical AG (VMED.HM)

Viromed Medical AG: UMECO Group Acquires Exclusive Marketing Rights in Asia for Cold Plasma Medical Devices ViroCAP(R) and PulmoPlas(R)

Viromed Medical AG Reports Promising Study Results for PulmoPlas(R) in Intensive Care Unit Ventilator-Associated Pneumonia Patients

Viromed Medical AG reaches milestone for cooperation with multinational corporation

Viromed Medical AG: Cold Plasma as a Digital Antibiotic for the Lungs

Viromed Medical AG Plans to Acquire All Shares of ActivCell Group AG by Way of a Capital Increase Against Contribution in Kind with Exclusion of Subscription Rights

Performance Overview